SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab ($RKLB) is trending amid discussions of potential contract wins and excitement surrounding upcoming launches, including Neutron. The community is buzzing about the company's growth potential and future prospects, with some speculating on a possible surge to new highs. However, some investors remain cautious, citing valuation concerns and recent downgrades.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending amid a significant sell-off, with community members debating whether key support levels will hold. Discussions revolve around potential dilution from share lock-up expirations and comparisons to similar brokerages like Robinhood ($HOOD). Some traders see the dip as a buying opportunity, while others express concerns about the stock's performance and future prospects.

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

Galecto Inc

GLTO is trending as traders actively discuss its recent volatile surge, drawing comparisons to other high-flying stocks like $SPRB. Community chatter revolves around potential short squeezes, low float dynamics, and whether it can sustain its gains. The stock's significant price movement and high trading volume are also key points of discussion.

BTQ Technologies Corp. engages in the business of post-quantum encryption. It focuses on applications to the blockchain industry. Its products include PQScale, Keelug, Kenting, Preon, QPoW, and QByte. The company was founded by Nicolas Roussy Newton on March 26, 2021 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQ Technologies Corp is trending as investors are excited about the company's advancements in post-quantum cryptography, especially after the announcement of key semiconductor experts joining the team. Community discussions highlight BTQ's potential for growth in the quantum security space and its relatively low market cap compared to competitors, with some drawing comparisons to early-stage opportunities in the crypto market.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as investors react to a boosted price target from Benchmark, sparking debates about the company's valuation and future potential in the quantum computing space. The community is actively discussing whether this rally is sustainable, with some pointing to the company's lack of profitability and potential for dilution, while others remain optimistic about its long-term prospects and recent contracts.

AlphaTON Capital Corp. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. Its portfolio includes first-in-class invariant natural killer T cell (iNKT) small molecule engagers and best-in-class adenosine antagonists. The company was founded by Gregory H. Bailey and James Mellon in 1973 and is headquartered in Road Town, British Virgin Islands.

AlphaTON Capital Corp.

AlphaTON Capital Corp. is trending as community members discuss its potential for significant price movement, drawing comparisons to other low-float stocks that have recently experienced rapid gains. The company's focus on TON tokens and a strategic partnership are being highlighted, with some anticipating news related to crypto. Additionally, some traders are noting the stock's high short interest and low float.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending following news of a $75 million investment from an institutional investor, sparking speculation about the investor's identity with community members eyeing names like NVDA and LUMN.  The excitement centers around POET's Optical Interposer technology, which aims to improve AI data center efficiency. Community members are focused on potential new partnerships and the long-term growth prospects for the company.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending due to its inclusion in the White House's eVTOL pilot program, seen as a significant step towards commercialization amid growing interest in the electric aviation sector. The community is actively discussing the stock's potential, partnerships, and milestones related to FAA certification, balancing optimism with concerns about valuation and profitability. Some investors are drawing comparisons to Archer Aviation ($ACHR) and considering sector rotation strategies.

Fitell Corp. engages in the business of selling gym and fitness equipment. It also offers turnkey solution for personal training studios and commercial gym chains. Its brands include Muscle Motion, Rapid Motion, and FleetX. The company was founded in 2007 and is headquartered in Sydney, Australia.

Fitell Corp - Ordinary Shares - Class A

Fitell Corp

FTEL is trending due to its low float and recent news regarding Solana treasury expansion and Nasdaq extension approval, leading to speculation of a potential breakout; the community is actively discussing squeeze potential and price target of 19.25, with some noting price discrepancies across different platforms; others are considering the stock as a potential play in the fitness equipment sector.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending due to anticipation surrounding upcoming data releases and presentations, especially regarding their gene therapy programs. Community members are actively discussing the potential impact of this data on regulatory approvals and the company's market position, with some speculating about a short squeeze. Positive sentiment is building around the long-term potential of Sarepta's pipeline, including their work with RNA therapies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Sonnet BioTherapeutics, Inc. (SONN) soared on Monday after the company entered a definitive business combination agreement with Rorschach I LLC to build a reserve of HYPE, the token of the Hyperliquid Layer-1 blockchain.<a href="https://stocktwits.com/symbol/SONN">SONN shares</a> were trading 82% higher on Monday afternoon at the time of writing.At the closing of the transaction, the newly-created entity is to be named Hyperliquid Strategies Inc. (HSI), which is expected to hold approximately 12.6 million HYPE tokens, representing $583 million in value shortly before agreement signing and gross cash invested of at least $305 million, for a total assumed closing value of $888 million.The gross cash proceeds of $305 million at closing will enable HSI to acquire significantly more HYPE, creating one of the top strategic reserves of the HYPE token, the company said.HSI is expected to remain listed on the Nasdaq under a new ticker symbol and become a public cryptocurrency treasury company upon the closing of the transaction.Sonnet will operate as a wholly-owned subsidiary of HSI and will continue focusing on existing assets and business lines, including the development of its investigational cancer drug SON-1010, while disposing of other assets.Bob Diamond, co-founder and CEO of Atlas Merchant Capital LLC, will be named Chairman of the Board, and David Schamis, CIO and Co-founder of Atlas, will be named Chief Executive Officer of HSI.It is expected that current owners of Rorschach and other new investors at closing will own approximately 98.8% of HSI, and the legacy stockholders of SONN will own the remaining approximately 1.2%.Raghu Rao, interim CEO of Sonnet, said that with the transaction, the company will be able to capitalize on the recent advancements around digital assets and equip Sonnet with funding to potentially realize the future value of its existing biotech assets.Sonnet will also raise an aggregate $5.5 million in a private placement as part of the agreement, which is expected to close on July 14.The business combination agreement is now subject to approval by Sonnet stockholders and other customary closing conditions. The closing of the business combination is expected to occur in the second half of this year.On Stocktwits, retail sentiment around Sonnet is unchanged within ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:625/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_14_at_2_14_50_PM_png_b81036dcad.webp" alt="SONN's Sentiment Meter and Message Volume as of 2:15 p.m. ET on July 14, 2025 | Source: Stocktwits" width="625" height="62"><figcaption>SONN's Sentiment Meter and Message Volume as of 2:15 p.m. ET on July 14, 2025 | Source: Stocktwits</figcaption></figure>SONN stock is up by 545% this year and by 32% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/rivian-ceo-transfers-portion-of-holdings-to-ex-wife-as-part-of-divorce-settlement/ch893xvR5nB">Rivian CEO Transfers Portion Of Holdings In EV Maker To Ex-Wife As Part Of Divorce Settlement</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Sonnet BioTherapeutics Stock Jumps 82% After Deal With Rorschach I: Retail Stays Exuberant

Shares of Sonnet BioTherapeutics, Inc. (SONN) soared on Monday after the company entered a definitive business combination agreement with Rorschach I LLC to build a reserve of HYPE

Equity

At the closing of the transaction, the newly created combined entity will be named Hyperliquid Strategies Inc., which is expected to hold approximately 12.6 million HYPE tokens.

Sonnet BioTherapeutics Advances SON-080 into Phase 2 Trials

Sonnet BioTherapeutics Holdings (SONN) just unveiled an update. Promising results from the Phase 1b trial of SON-080 for chemotherapy-induced perip...

Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting

PRINCETON, NJ / ACCESSWIRE / March 19, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ('Sonnet' or the 'Company'), a biopharmaceutical company developing innovative targeted biologic...

Sonnet BioTherapeutics Announces Early Safety Data from the Company's Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study's Initial Pre-Specified Objective

Safety in the Phase 1b part of Sonnet's double-blind, randomized, controlled trial of SON-080 was reviewed by the study's Data Safety Monitoring Board (DSMB)The adverse event profile and tolerability...

Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers

PRINCETON, NJ / ACCESSWIRE / February 29, 2024 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today...

Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update

Successfully raised approximately $4.55 million in gross proceeds through an underwritten public offeringExtensive preclinical data on SON-1210 published in Frontiers in ImmunologyReceived approval...

BTIG Reaffirms Their Buy Rating on Sonnet BioTherapeutics Holdings (SONN)

BTIG analyst Kaveri Pohlman maintained a Buy rating on Sonnet BioTherapeutics Holdings (SONN Research Report) on January 5 and set a price target...

Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. Its Fully Human Albumin Binding (FHAB) technology utilizes a single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its pipeline focuses on cytokines, a class of cell signaling peptides that, among other important functions, serve as potent immunomodulatory agents. The company was founded by Pankaj Mohan and John K. Cini in 2011 and is headquartered in Princeton, NJ.

Sonnet BioTherapeutics Holdings Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

SONN Sonnet BioTherapeutics Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SONN News